ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

ADAMA posts $62 mln H1 2026 profit as pricing pressure persists

Revenue essentially flat year-over-year at $7.27 billion; gross margin expands to 32% despite 4% average price decline across markets.

PA
Priya Anand · Equities & Earnings Desk · 25 Aug 2026 · 16:02 · 2 min read
Share
ADAMA posts $62 mln H1 2026 profit as pricing pressure persists

ADAMA Ltd. reported a $62 million net profit for the first half of 2026, reversing a $11 million loss in the same period last year, as the agrochemical producer navigated sustained pricing headwinds. Revenue remained essentially flat at $7.27 billion, while gross profit rose 6% to $632 million, lifting gross margin to 32% from 30% in H1 2025.

Adjusted net income increased 28% year-over-year, though adjusted EBITDA declined 3% to $302 million. Operating cash flow fell to $100 million from $242 million, a decline executives attributed to timing-related collection delays and inventory accumulation tied to the Israeli entity merger. Free cash flow totaled $54 million, down from $90 million in the prior-year period.

Volume growth of 1% offset a 4% average price decline across markets, with management noting a 3% increase excluding the closure of the Anpon asset. The company launched 23 products and secured 54 registration certificates during the period, advancing its shift toward higher-margin, differentiated offerings.

Shares of ADAMA traded flat in after-hours at $5.50, later slipping to $5.46, a 1.62% decline from the prior close of $5.55. The stock has ranged between $5 and $7.63 over the past 52 weeks.

For the full year 2026, ADAMA maintained revenue guidance at $4.559 billion and projected earnings per share of $0.04. The company expects market volumes to remain stable but pricing pressure to persist through year-end, with higher raw material costs anticipated to weigh more heavily on results in the second half. A planned return to sales in Turkey is projected to have a modest impact in 2026 and a larger effect in 2027.

Executives emphasized the transition from a stabilization phase to a new growth strategy, dubbed "Growing Forward," focused on portfolio differentiation, commercial execution, cost competitiveness, and operational optimization. CEO Gaël Hili stated the company aims to strengthen its position as a top post-patent synthetic chemistry provider, while CFO Efrat Nagar noted the cash flow decline was not structural but tied to temporary factors.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Novara — A Smarter Way to Access Global Markets
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT